Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 8;3(3):482-513.
doi: 10.3390/ph3030482.

The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis

Affiliations
Review

The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis

Domenico Ribatti. Pharmaceuticals (Basel). .

Abstract

Antiangiogenesis, e.g., inhibition of blood vessel growth, is being investigated as a way to prevent the growth of tumors and other angiogenesis-dependent diseases. Pharmacological inhibition interferes with the angiogenic cascade or the immature neovasculature with synthetic or semi-synthetic substances, endogenous inhibitors or biological antagonists.The chick embryo chorioallantoic membrane (CAM) is an extraembryonic membrane, which serves as a gas exchange surface and its function is supported by a dense capillary network. Because its extensive vascularization and easy accessibility, CAM has been used to study morphofunctional aspects of the angiogenesis process in vivo and to study the efficacy and mechanism of action of pro- and anti-angiogenic molecules. The fields of application of CAM in the study of antiangiogenesis, including our personal experience, are illustrated in this review article.

Keywords: antiangiogenesis; chorioallantoic membrane; tumor progression.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ribatti D., Nico B., Crivellato E., Roccaro A.M., Vacca A. The history of the angiogenic switch concept. Leukemia. 2007;21:44–52. - PubMed
    1. Folkman J. Tumor angiogenesis: Therapeutic implications. New Engl. J. Med. 1971;285:1182–1186. - PubMed
    1. Nyberg P., Xie L., Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005;65:3967–3979. doi: 10.1158/0008-5472.CAN-04-2427. - DOI - PubMed
    1. Ellis L.M. Bevacizumab. Nat. Rev. Drug Discov. 2005:S8–S9. - PubMed
    1. Norrby K. In vivo models of angiogenesis. J. Cell. Mol. Med. 2006;10:588–612. doi: 10.1111/j.1582-4934.2006.tb00423.x. - DOI - PMC - PubMed

LinkOut - more resources

-